Susanne Stowasser Selected Research

nintedanib

1/2022	Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trial.
1/2022	Challenges for Clinical Drug Development in Pulmonary Fibrosis.
1/2022	Meta-Analysis of Effect of Nintedanib on Reducing FVC Decline Across Interstitial Lung Diseases.
1/2022	Nintedanib in Patients With Autoimmune Disease-Related Progressive Fibrosing Interstitial Lung Diseases: Subgroup Analysis of the INBUILD Trial.
10/2021	Efficacy and safety of nintedanib in Japanese patients with progressive fibrosing interstitial lung diseases: Subgroup analysis of the randomised, double-blind, placebo-controlled, phase 3 INBUILD trial.
4/2021	Study design of a randomised, placebo-controlled trial of nintedanib in children and adolescents with fibrosing interstitial lung disease.
3/2021	Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases.
1/2021	Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial.
1/2020	Health-related quality of life and symptoms in patients with IPF treated with nintedanib: analyses of patient-reported outcomes from the INPULSIS® trials.
1/2020	Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Susanne Stowasser Research Topics

Disease

40	Idiopathic Pulmonary Fibrosis 01/2022 - 05/2014
16	Disease Progression 01/2020 - 05/2014
12	Interstitial Lung Diseases (Interstitial Lung Disease) 01/2022 - 01/2019
6	Fibrosis (Cirrhosis) 01/2020 - 05/2015
5	Systemic Scleroderma (Systemic Sclerosis) 01/2022 - 01/2019
4	Diarrhea 01/2022 - 05/2014
3	Pulmonary Fibrosis (Fibrosing Alveolitis) 01/2022 - 01/2020
2	Lung Diseases (Lung Disease) 01/2022 - 10/2019
2	Emphysema 01/2020 - 01/2019
2	Extrinsic Allergic Alveolitis (Hypersensitivity Pneumonitis) 01/2020 - 01/2019
2	Hemorrhage 01/2019 - 01/2019
1	Autoimmune Diseases (Autoimmune Disease) 01/2022
1	Body Weight (Weight, Body) 04/2021
1	Lung Neoplasms (Lung Cancer) 01/2020
1	Idiopathic Interstitial Pneumonias 01/2020
1	Lung Injury 03/2019
1	Diffuse Scleroderma (Progressive Systemic Sclerosis) 01/2019
1	Nausea 01/2019
1	Silicosis 01/2019
1	Vomiting 01/2019
1	Rheumatoid Arthritis 01/2019
1	Myocardial Infarction 01/2019
1	Dyspnea (Shortness of Breath) 11/2018
1	Bronchiectasis 01/2017
1	Chronic Obstructive Pulmonary Disease (COPD) 10/2013

Drug/Important Bio-Agent (IBA)

44	nintedanibIBA 01/2022 - 05/2014
7	pirfenidoneIBA 01/2022 - 01/2015
4	Carbon MonoxideIBA 01/2022 - 10/2019
3	Tyrosine Kinase InhibitorsIBA 01/2020 - 01/2019
3	Tyrosine (L-Tyrosine)FDA Link 10/2019 - 01/2019
3	Phosphotransferases (Kinase)IBA 10/2019 - 01/2019
2	Sildenafil Citrate (Viagra)FDA Link 12/2019 - 11/2018
2	Biomarkers (Surrogate Marker)IBA 01/2019 - 01/2018
1	Type 4 Cyclic Nucleotide PhosphodiesterasesIBA 01/2022
1	Pharmaceutical PreparationsIBA 01/2022
1	BI 1015550IBA 01/2022
1	cyclopropapyrroloindoleIBA 01/2020
1	Brain Natriuretic Peptide (Natrecor)FDA Link 12/2019
1	EnzymesIBA 01/2019
1	Therapeutic UsesIBA 01/2019
1	catch-relaxing peptide (Mytilus)IBA 01/2019
1	AcidsIBA 09/2018
1	Proteins (Proteins, Gene)FDA Link 01/2018
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2018
1	Adrenal Cortex Hormones (Corticosteroids)IBA 10/2013
1	Anti-Bacterial Agents (Antibiotics)IBA 10/2013
1	Tiotropium Bromide (Spiriva)FDA Link 10/2013

Therapy/Procedure

4	Therapeutics 04/2021 - 01/2018
1	Drug Tapering 04/2021
1	Immunomodulation 03/2021
1	Precision Medicine 01/2020
1	Lung Transplantation 01/2020
1	Traction 01/2017